Challenges and opportunities for improving access to approved neonatal drugs and devices

Abstract
Neonatal drug and device development has lagged behind other patient populations. Oftentimes, providers are using drugs and devices without adequate study of safety and efficacy. Neonates deserve dedicated drug and device development programs, which will require novel approaches and unique collaborations between multiple key stakeholders.

Read the source article at Nature
2022-02-07 00:00:00